Formulary Monographs [SACUBITRIL|VALSARTAN, 243208]
|
|
SACUBITRIL | VALSARTAN
|
|
|
|
|
|
ANGIOTENSIN II RECEPTOR ANTAGONIST
|
|
|
Sacubitril and valsartan in fixed combination is used to reduce the risk of cardiovascular death and hospitalization for patients with chronic heart failure (New York Heart Association [NYHA] class 11-1V and reduced ejection fraction, in patients not curr
|
|
|
A history of angioedema with an ACE inhibitor or angiotensin 11receptor antagonist. Concomitant use with ACE inhibitors. Sacubitril/valsartan should not be administered within 36 hours of switching from or to an ACE inhibitor. Concomitant use of aliskiren in patients with diabetes. Fixed combinations containing ACE inhibitors or ARB can cause fetal and neonatal morbidity and mortality when used in the 2nd and 3rd trimesters. Should be discontinued as soon as possible when pregnancy is detected. Dose reduction or discontinuation is needed in patients with reduce renal function. Hypotension, hyperkalemia, cough, dizziness, and renal failure or acute renal failure.
|
|
|
Adult: The recommended initial dose of sacubitril /valsartan in patients with CHF who are stabilised on an ACE or ARB is sacubitril 49mg /valsartan 51 mg twice daily. 36 hours should have relapsed before starting sacubitril/valsartan, if patient was on a
|
|
|
|
|
|
|
|
|
|
|
|
|